To study the clinical efficacy and nephrotoxicity along with the risk factors for acute kidney injury associated with parenteral polymyxin B

Indian Journal of Critical Care Medicine

Volumn 17, Issue 5, 2013, Pages 283-287

  Nandha, Ruchika ^a   Sekhri, Kavita ^a   Mandal, Amit ^b  

^a PANJAB UNIVERSITY   (India)

^b FORTIS HOSPITAL   (India)

Author keywords

Acinetobacter baumannii; acute kidney injury; multidrug resistance gram ve septicemia; nephrotoxicity; polymyxin B

Indexed keywords

POLYMYXIN B;

ACINETOBACTER BAUMANNII; ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; INDIA; INTENSIVE CARE UNIT; KIDNEY FUNCTION; MALE; MORTALITY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; PILOT STUDY; POLYPHARMACY; RECOMMENDED DRUG DOSE; RISK FACTOR; TREATMENT INDICATION;

EID: 84889656197     PISSN: 09725229     EISSN: 1998359X     Source Type: Journal    
DOI: 10.4103/0972-5229.120319     Document Type: Article

References (25)

1. Levy SB, Marshall B. Antibacterial resistance worldwide: Causes, challenges and responses. Nat Med 2004;10:S122-9. (Pubitemid 40018235)
2. Bassetti M, Ginocchio F, Mikulska M. New treatment options against gram-negative organisms. Crit Care 2011;15:215.
3. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006;42 Suppl 2:S82-9. (Pubitemid 43054219)
4. Rossolini GM, Mantengoli E, Docquier JD, Musmanno RA, Coratza G. Epidemiology of infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant strains. New Microbiol 2007;30:332-9. (Pubitemid 47264901)
5. Trivedi TH, Sabnis GR. Superbugs in ICU: Is there any hope for solution J Assoc Physicians India 2009;57:623-5.
6. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. J Infect Dis 2008;197:1079-81. (Pubitemid 351590040)
7. Mehta A, Rosenthal VD, Mehta Y, Chakravarthy M, Todi SK, Sen N, et al. Device-associated nosocomial infection rates in intensive care units of seven Indian cities. Findings of the International Nosocomial Infection Control Consortium (INICC). J Hosp Infect 2007;67:168-74.
8. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG, et al. Bad bugs need drugs: An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006;42:657-68. (Pubitemid 43271379)
9. Kvitko CH, Rigatto MH, Moro AL, Zavascki AP. Polymyxin B versus other antimicrobials for the treatment of pseudomonas aeruginosa bacteraemia. J Antimicrob Chemother 2011;66:175-9.
10. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: Results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 2011;66:2070-4.
11. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin Microbiol Rev 2008;21:449-65.
12. Mendes CA, Cordeiro JA, Burdmann EA. Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use. Ann Pharmacother 2009;43:1948-55.
13. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother 2003;47:2659-62. (Pubitemid 36919476)
14. Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother 2004;54:566-9. (Pubitemid 39177490)
15. Holloway KP, Rouphael NG, Wells JB, King MD, Blumberg HM. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann Pharmacother 2006;40:1939-45. (Pubitemid 44747462)
16. Ramasubban S, Majumdar A, Das PS. Safety and efficacy of polymyxin B in multidrug resistant Gram-negative severe sepsis and septic shock. Indian J Crit Care Med 2008;12:153-7.
17. Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: A critical review. J Antimicrob Chemother 2007;60:1206-15. (Pubitemid 350168315)
18. Falagas ME, Kasiakou SK. Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-41. (Pubitemid 40570245)
19. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: The re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006;6:589-601.
20. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: Old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999;33:960-7. (Pubitemid 29420995)
21. Hermsen ED, Sullivan CJ, Rotschafer JC. Polymyxins: Pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect Dis Clin North Am 2003;17:545-62.
22. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med 1985;13:818-29. (Pubitemid 15250137)
23. Product Information. Inj. Polymyxin B sulphate BP 50,000 units, Samarth Poly B. Mumbai: Samarth Life Sciences private limited; 2010.
24. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
25. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative workgroup. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204-12.